超45亿美元BD和入股,和铂医药拿下MNC大单

医药魔方
Mar 25

最懂中国的MNC,又出手了!3月21日,阿斯利康中国官宣了25亿美元投资计划,在北京建立第六个全球战略研发中心,并达成多项重大研发与生产合作。在这一投资版图中,和铂医药是一个不容忽视的存在。同一天,双方凭借潜在总交易金额45.75亿美元的BD交易,刷新了2025年中国创新药BD交易纪录,同时,更以“授权合作+股权投资”的形式,贡献了又一起MNC深度参与中国创新药的案例。值得注意的是,这并非和铂医药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10